292 related articles for article (PubMed ID: 24793444)
1. An assessment by the Statin Intolerance Panel: 2014 update.
Guyton JR; Bays HE; Grundy SM; Jacobson TA; The National Lipid Association Statin Intolerance Panel
J Clin Lipidol; 2014; 8(3 Suppl):S72-81. PubMed ID: 24793444
[TBL] [Abstract][Full Text] [Related]
2. An assessment by the Statin Muscle Safety Task Force: 2014 update.
Rosenson RS; Baker SK; Jacobson TA; Kopecky SL; Parker BA; The National Lipid Association's Muscle Safety Expert Panel
J Clin Lipidol; 2014; 8(3 Suppl):S58-71. PubMed ID: 24793443
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.
Mancini GB; Tashakkor AY; Baker S; Bergeron J; Fitchett D; Frohlich J; Genest J; Gupta M; Hegele RA; Ng DS; Pearson GJ; Pope J
Can J Cardiol; 2013 Dec; 29(12):1553-68. PubMed ID: 24267801
[TBL] [Abstract][Full Text] [Related]
4. An assessment by the Statin Cognitive Safety Task Force: 2014 update.
Rojas-Fernandez CH; Goldstein LB; Levey AI; Taylor BA; Bittner V; The National Lipid Association's Safety Task Force
J Clin Lipidol; 2014; 8(3 Suppl):S5-16. PubMed ID: 24793442
[TBL] [Abstract][Full Text] [Related]
5. An assessment by the Statin Liver Safety Task Force: 2014 update.
Bays H; Cohen DE; Chalasani N; Harrison SA; The National Lipid Association's Statin Safety Task Force
J Clin Lipidol; 2014; 8(3 Suppl):S47-57. PubMed ID: 24793441
[TBL] [Abstract][Full Text] [Related]
6. Statin Intolerance: Some Practical Hints.
Banach M; Mikhailidis DP
Cardiol Clin; 2018 May; 36(2):225-231. PubMed ID: 29609752
[TBL] [Abstract][Full Text] [Related]
7. NLA Task Force on Statin Safety--2014 update.
Jacobson TA
J Clin Lipidol; 2014; 8(3 Suppl):S1-4. PubMed ID: 24793438
[No Abstract] [Full Text] [Related]
8. Statin Intolerance: the Clinician's Perspective.
Stulc T; Ceška R; Gotto AM
Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
[TBL] [Abstract][Full Text] [Related]
9. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).
Mancini GB; Baker S; Bergeron J; Fitchett D; Frohlich J; Genest J; Gupta M; Hegele RA; Ng D; Pearson GJ; Pope J; Tashakkor AY
Can J Cardiol; 2016 Jul; 32(7 Suppl):S35-65. PubMed ID: 27342697
[TBL] [Abstract][Full Text] [Related]
12. An assessment of statin safety by neurologists.
Brass LM; Alberts MJ; Sparks L;
Am J Cardiol; 2006 Apr; 97(8A):86C-88C. PubMed ID: 16581335
[TBL] [Abstract][Full Text] [Related]
13. [Practical approach to statin intolerance].
Štulc T; Beránková Š; Češka R
Vnitr Lek; 2015 Nov; 61(11):936-41. PubMed ID: 26652780
[TBL] [Abstract][Full Text] [Related]
14. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
15. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
16. [Statin therapy--for whom?].
Kahri J; Syvänne M
Duodecim; 2012; 128(8):811-8. PubMed ID: 22616372
[TBL] [Abstract][Full Text] [Related]
17. An assessment by the Statin Diabetes Safety Task Force: 2014 update.
Maki KC; Ridker PM; Brown WV; Grundy SM; Sattar N; The Diabetes Subpanel of the National Lipid Association Expert Panel
J Clin Lipidol; 2014; 8(3 Suppl):S17-29. PubMed ID: 24793439
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
19. Statin tolerability: In defence of placebo-controlled trials.
Tobert JA; Newman CB
Eur J Prev Cardiol; 2016 May; 23(8):891-6. PubMed ID: 26318980
[TBL] [Abstract][Full Text] [Related]
20. Statins and cognitive side effects: what cardiologists need to know.
Rojas-Fernandez C; Hudani Z; Bittner V
Cardiol Clin; 2015 May; 33(2):245-56. PubMed ID: 25939297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
